BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25511698)

  • 1. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
    Tréhoux S; Duchêne B; Jonckheere N; Van Seuningen I
    Biochem Biophys Res Commun; 2015 Jan; 456(3):757-62. PubMed ID: 25511698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
    Zhao Y; Shen S; Guo J; Chen H; Greenblatt DY; Kleeff J; Liao Q; Chen G; Friess H; Leung PS
    J Surg Res; 2006 Dec; 136(2):325-35. PubMed ID: 17054996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 regulates PDGFA expression during pancreatic cancer progression.
    Sahraei M; Roy LD; Curry JM; Teresa TL; Nath S; Besmer D; Kidiyoor A; Dalia R; Gendler SJ; Mukherjee P
    Oncogene; 2012 Nov; 31(47):4935-45. PubMed ID: 22266848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
    Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.
    Besmer DM; Curry JM; Roy LD; Tinder TL; Sahraei M; Schettini J; Hwang SI; Lee YY; Gendler SJ; Mukherjee P
    Cancer Res; 2011 Jul; 71(13):4432-42. PubMed ID: 21558393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
    Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
    Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
    Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
    Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
    World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
    Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
    Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
    Shimizu K; Chiba S; Hori Y
    PLoS One; 2013; 8(11):e81283. PubMed ID: 24278411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
    Pham NA; Tsao MS; Cao P; Hedley DW
    Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.